$OMCL

Vanguard holds 2.27M shares in Omnicell (NASDAQ: OMCL)

Vanguard Capital Management has disclosed beneficial ownership of 2,274,766 shares of Omnicell (NASDAQ: OMCL) common stock, representing a 5% stake. This filing, a Schedule 13G, indicates a passive investment rather than an intent to influence the company. Vanguard holds sole dispositive power over all these shares and sole voting power over 340,249 shares.

Original reporting
Published May 1, 2026, 1:39 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 1, 2026, 2:00 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefFinancial news
Primary signal
$OMCL
Neutral
medium confidence
Mentioned
$OMCL · $OMCL
alphai data visualization · based on Stock Titan
Decision brief

The 30-second read

$OMCLNeutralLow
01

Why it matters

The disclosure is unlikely to cause immediate market movements but may influence perceptions of institutional confidence.

02

Market read

The news has limited short-term trading impact but provides insight into institutional holdings, which can be relevant for long-term investors.

03

What to watch

The passive nature of Vanguard's holdings suggests no active influence; market reactions are unlikely unless new developments occur.

Timing: long-term

Background

Vanguard's disclosure of a 5% passive stake in Omnicell indicates a significant institutional position, aligning with typical passive investment strategies.

Company-level read

Ticker impact

$OMCLNeutralMedium confidence
Context

The disclosed passive ownership of 5% by Vanguard indicates a significant institutional position, but as a passive investor, it does not imply immediate strategic moves or influence.

Expected impact

Minimal short-term price movement expected; potential for slight stabilization or support at current levels.

Evidence & confidence

Passive ownership typically does not lead to aggressive trading actions. The low relevance score and neutral sentiment support a cautious outlook.

$OMCLNeutralMedium confidence
Context

Same as above; the focus is on Vanguard's passive stake, which does not directly affect trading strategies.

Expected impact

No significant price change anticipated from this disclosure.

Evidence & confidence

Passive investors generally do not trigger rapid market movements unless accompanied by active trading signals.

Market effects

Potential stabilization in the healthcare equipment sector; no immediate sector-wide shifts expected.

Limited regional impact; the news pertains primarily to U.S.-based company and investor.

Negligible; the event is specific to U.S. institutional holdings.

Counterpoint

Some traders might interpret the passive stake as a sign of confidence, potentially supporting the stock.

Key entities

  • Vanguard Capital Management

    A major investment management firm known for passive investment strategies.

  • Omnicell (NASDAQ: OMCL)

    A healthcare technology company specializing in medication management solutions.

Related articles

$OMCLMed

OMCL Falls 20.1% in a Month as Booking and Margin Risks Build

Omnicell (OMCL) shares fell 20.1% over four weeks. The company reported Q2 2026 adjusted EPS of $0.94, up 108.9% y/y, and revenue of $312.2M, up 7.4%. Omnicell raised 2026 non-GAAP EPS to $2.15-$2.30 and EBITDA to $175-$185M, but expects $6M incremental memory-chip costs, weaker product bookings ($425-$560M) and lower annual recurring revenue ($660-$680M).

$OMCLMedAI 8/10

Omnicell (OMCL) Stock Trades Down, Here Is Why

Omnicell (NASDAQ: OMCL) shares fell 9.9% after the company reported Q2 results that beat expectations but issued weaker guidance. Omnicell posted Q2 revenue of $312.2 million and adjusted EPS of $0.94. For Q3, it projected revenue of about $304 million, below estimates, and next-quarter EPS guidance missed consensus.

$OMCLHigh

OMNICELL, INC. (OMCL): Results of Operations and Financial Condition

OMNICELL, INC. (OMCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Contact: Omnicell, Inc. David Unger 4220 North Freeway Vice President, Investor Relations Fort Worth, TX 76137 ir@omnicell.com Omnicell Announces Second Quarter 2026 Financial Results Omnicell delivers solid second quarter 2026 financial results Updates full year 202

$VOW3.DELow

Volkswagen Names New North America Chief

Volkswagen appointed Marco Schubert as North America chief, replacing Kjell Gruner. Schubert will join the Extended Executive Committee on Oct. 1. The move follows declining U.S. sales, down 13.6% in 2025 and 7.4% in H1 2026. Schubert has 25+ years of experience at Volkswagen Group, including roles at Audi, Skoda, and Porsche.

$MRKMed

Is Merck Stock Pricing In A Post-Keytruda Future Too Soon?

Merck (MRK) stock has surged 84% in the past year, outperforming peers, despite its revenue growth and profitability lagging. The market is betting on its pipeline, valued at over $70B, to offset Keytruda's patent expiration. LIPFENDRA's launch and sales will be key indicators of Merck's ability to deliver on its future prospects.